Alto Pharmacy Stock $6.22

Forge Price BeaconForge Price 1 updated December 2, 2024

alto.comHealthcare / Digital HealthFounded: 2015Funding to Date: $1.24B

Alto Pharmacy is a digital pharmacy focused on delivering prescriptions to patients without delivery fees. As with physical pharmacies, patients are able to chat directly with Alto pharmacists to ask questions about their care across general health, sexual health, heart health, fertility, and more. Alto Pharmacy was founded in 2015 by Jamie Karraker, Mattieu Gamache-Asselin, and Vladimir Blumen and is headquartered in San Francisco, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Alto Pharmacy, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Alto Pharmacy Stock Price

3M
6M
1Y
MAX
Forge Price 1
Date
12/02/2024
Price per Share
$6.22
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Alto Pharmacy Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/25/2023 Series EE-1 $2.44MM $xx.xx $798.78MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
143,458
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/25/2023 Series CC-4 $6.3MM $xx.xx $798.78MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,388,698
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/25/2023 Series F $111.26MM $xx.xx $798.78MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
18,110,665
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
01/27/2022 Series EE $185.52MM $xx.xx $1.51B Softbank
Price per Share
$xx.xx
Shares Outstanding
12,000,128
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Softbank
02/04/2020 Series DD $246.4MM $xx.xx $751.58MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
Price per Share
$xx.xx
Shares Outstanding
25,130,023
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
06/19/2019 Series CC $30MM $xx.xx $261.15MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,830,751
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/05/2018 Series CC-3 $33,998.24 $xx.xx $164.84MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share
$xx.xx
Shares Outstanding
12,883
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
12/05/2018 Series CC-2 $9.38MM $xx.xx $164.84MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share
$xx.xx
Shares Outstanding
2,316,805
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
12/05/2018 Series CC-1 $41.03MM $xx.xx $164.84MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share
$xx.xx
Shares Outstanding
8,616,165
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
06/12/2017 Series BB $17.15MM $xx.xx $55.98MM Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
Price per Share
$xx.xx
Shares Outstanding
5,902,610
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
06/10/2016 Series AA-1 $649,991.76 $xx.xx $17.25MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
774,722
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/10/2016 Series AA $5.95MM $xx.xx $17.25MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,879,912
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Alto Pharmacy Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Alicia Davis
Chief Executive Officer
Nihar Bhatt
Chief Financial Officer
Mike McClay
Chief Technology Officer

Board

John Westcott
SoftBank Investment Advisers
Neil Shah
Greenoaks Capital Partners
Nichola Eliovits
Olive Tree Capital

Alto Pharmacy stock FAQs

plusminus

Can you buy Alto Pharmacy stock?

As Alto Pharmacy is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Alto Pharmacy, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Alto Pharmacy stock?

To invest in a private company like Alto Pharmacy through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Alto Pharmacy stock?

Yes, you may sell the Alto Pharmacy stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Alto Pharmacy stock?

If you hold private company shares of Alto Pharmacy – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Alto Pharmacy on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Alto Pharmacy a public company?

No, Alto Pharmacy is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Alto Pharmacy’s stock price?

Alto Pharmacy is a private company, meaning it does’t have a publicly traded stock price. However, as of 12/02/2024 the Alto Pharmacy Forge Price is $6.22 per share. The Forge Price is a derived price calculated for private companies like Alto Pharmacy to provide insights into their current valuation. Learn more about Forge Price.
plusminus

What is Alto Pharmacy’s stock ticker symbol?

Alto Pharmacy does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Alto Pharmacy News and Media Highlights

Mark Cuban Cost Plus Drug Company partners with Alto Pharmacy

Mark Cuban's Cost Plus Drug Company partners with Alto Pharmacy to provide low-cost prescription delivery to Team Cuban Card holders.

This Former Auto Executive Is Now CEO of a Billion-Dollar Online Pharmacy

Alicia Boler Davis was the most senior Black executive in the auto industry before joining Amazon, and later, Alto Pharmacy. Her mentors, she says, have pushed her to continually raise the bar for herself.

A Softbank-backed pharmacy startup is working to tackle a $300-billion-a-year prescription drug crisis

For years, the $500 billion prescription drug industry has loomed as an enticing target for disruption-minded entrepreneurs and corporations alike.

On track to hit $1B in revenue this year, Alto Pharmacy tapped an Amazon exec to lead its next phase of growth

Jamie Karraker and Mattieu Gamache-Asselin, who both previously worked at Facebook, bought an independent "mom-and-pop" pharmacy in San Francisco's Mission District to learn the workflows and pain points for consumers, doctors and pharmacists.
Browse Insights
Updated on: Dec 2, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.